Since November 2020, the FDA issued emergency use authorizations (EUA) for the use of the investigational SARS-CoV2 monoclonal antibody products: a combination monoclonal antibody called bamlanivimab and etesivimab manufactured by Eli Lilly and Company (Lilly), and a combination monoclonal antibody product called casirivimab and imdevimab manufactured by Regeneron. The drugs can be considered for the treatment of high-risk patients with mild to moderate Covid-19, who do not require supplemental oxygen therapy or additional oxygen therapy above their baseline.

The following monoclonal antibody therapies have demonstrated a reduction in hospitalizations and ER visits.

- a single infusion of bamlanivimab 700mg AND etesevimab 1400mg IV over 60 minutes OR
- a single infusion of casirivimab 1200mg/imdevimab 1200mg for a total of 2400mg IV over 60 minutes

These available monoclonal antibodies may be considered if the following criteria are met for patients with mild-moderate symptoms:

- Age ≥12 weighing at least 40 kg
- Not requiring any supplemental O2 or increase from baseline O2 requirements
- SARS-CoV-2 Positive test ≤ 7 days prior
- Symptom onset ≤ 7 days prior
- At least one high-risk criterion

High-risk criteria:
- Age ≥ 65 regardless of medical co-morbidities
- Diabetes
- Immunosuppressive disease or immunosuppressive therapy
- CKD (CrCl < 60 ml/min per Cockroft-Gault for > 3 months)
- Obesity (BMI ≥ 30) (or if 12-17 BMI ≥ 85th percentile (based on CDC growth chart))
- Neurologic diseases: cerebrovascular diseases, Down Syndrome or other neurodevelopmental disorders, or dementia
- Liver disease
- Pregnancy
- Smoking
- Hemoglobin disorders (sickle cell, thalassemia)
- Cardiovascular disease (congenital heart disease, heart failure, CAD, cardiomyopathy, or pulmonary HTN), OR Hypertension
- Chronic lung disease (COPD/emphysema, moderate-severe asthma, CF, pulmonary fibrosis)
- Medical-related technological dependence (tracheostomy, gastrostomy, or positive pressure ventilation not related to COVID-19)

Individuals coming from a disadvantaged socioeconomic background should be strongly considered given their increased risk of mortality. Please note the data on the benefit of this drug remain limited and per national guidance, these drugs should not be considered standard of care and are purely investigational. At this time, there are two pathways whereby patients may obtain these investigational drugs.

- Patients who are in the ER and meet the above criteria but do not meet the criteria for admission may be given either bamlanivimab/etesevimab or casirivimab/imdevimab. Please do not refer patients to the ER to receive these drugs given our current surge.
Other patients may be able to receive either drug at our designated infusion center after December 10, 2020. We have a centralized process whereby a clinical team will review all outpatients with positive tests who meet criteria. Our team will reach out to the ordering clinician to discuss the treatment with their patients and subsequently place a referral in Care Connect (REFERRAL FOR MONOCLONAL ANTIBODY INFUSION FOR COVID+ PATIENTS [REF1010]).

Clinicians may also place a referral on their own through Care Connect (REFERRAL FOR MONOCLONAL ANTIBODY INFUSION FOR COVID+ PATIENTS [REF1010]) as long as the criteria are met. Please note each referral will be cross-checked to ensure criteria have been met.

Please review the patient (Spanish) and provider fact sheets for bamlanivimab/etesevimab and the patient (Spanish) and provider fact sheets for casirivimab/imdevimab. All patients will be given a fact sheet prior to drug administration.

Given that the demand for these drugs will exceed our ability to administer on any given day, the order time stamp and a point system with measures to account for socioeconomic vulnerability will be included in the allocation process. We will review all referrals at 10:30am on each calendar day.

We have also included information provided by Coram, a CVS specialty infusion service, which has been designated by HHS to offer treatment to a small number of patients in Los Angeles County. Their dedicated intake team can be contacted at 866-316-0264 from Mon-Fri 8 am -5 pm.

Ongoing trials regarding the efficacy and safety of monoclonal antibodies, including ACTIV-2 here at UCLA, as well as other studies, remain open. Please send a message in Care Connect to the COVID Research Pool for more details.

These agents are primarily to be used in the outpatient setting. However, select hospitalized patients may be considered with ID approval.